MM RX IB Exit Opportunities?

Curious to hear what exits one might see coming from an RX IB platform like JEF/Baird/Piper/*. Looking to go into distressed PE or HFs. I understand some of the firms listed don't have a huge presence; will that negatively impact me dramatically when it comes to interviewing (i.e. potentially lacking strong deal experience, maybe a lot more pitching) despite having an interesting background?

Would I be stuck looking at MM Distressed PE/HF or is there any hope for an UMM distressed PE or strong distressed HF shop?

10 Comments
 

I would not consider going to one of the MM RX firms unless it is your only option. You would be better on the M&A side if you get to pick. The problem with these firms, is even though a firm like Jefferies is on some large cases, they are typically not in a leadership position (not advising the fulcrum or the company). Jefferies for instance often advises the unsecured creditor committee, and in that position, you are not as involved and just won't get close to the deal experience that you get advising the fulcrum or the company. As you mentioned, it will also be a lot of pitching for a leadership role in the deal, only to lose to a top firm than settling to advise the UCC or for some other less involved role. And when it come to recruiting for UMM distressed PE, you just won't get the looks that a top RX firm would get. In terms of exposure and deal experience, it would just be difficult to compete against analyst from the top shops or even mid-tier shops like Gugg, Ducera, and PWP because they are getting great exposure from a leadership position, and all these analyst are competing for relatively few positions. If you do end up at one of these shops and want UMM PE/HF then lateraling to a mid or top tier firm would be your best best (which is tough because rx is slow right now). 

 
Most Helpful

Est sint quasi ut ducimus quisquam eos. Id est similique et quia dolorem adipisci quisquam. Excepturi nobis ut laborum veniam at dolor. Facilis hic sunt nostrum rerum aut quam facere culpa.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 12 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (79) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
dosk17's picture
dosk17
98.9
6
CompBanker's picture
CompBanker
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
DrApeman's picture
DrApeman
98.9
9
GameTheory's picture
GameTheory
98.9
10
Mimbs's picture
Mimbs
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”